Both reported and organic revenue for the fiscal first quarter of 2025 exclude the acquired Gynesonics business, which closed in Hologic's fiscal second quarter of 2025. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID-19 assay revenue, COVID-19 related sales of instruments, COVID-19 related revenue from Diagenode and Mobidiag, collection kits and ancillaries, as well as license revenue, and revenues from discontinued products.